|Bid||191.88 x 100|
|Ask||191.92 x 200|
|Day's Range||189.46 - 192.57|
|52 Week Range||150.38 - 192.57|
|PE Ratio (TTM)||17.33|
|Forward Dividend & Yield||5.28 (2.79%)|
|1y Target Est||N/A|
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
The Zacks Analyst Blog Highlights: UnitedHealth, Amgen, United Technologies, CSX and General Dynamics
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal.